![]() 编者按 追本溯源——肠道黏膜免疫失调在IgA肾病中起重要作用 靶向回肠——布地奈德肠溶胶囊作用于肠道黏膜免疫 注:*人体血管收缩模型(表现为皮肤血流减少、变白)被作为糖皮质激素效力评估的替代标志 何以“赋”康——布地奈德肠溶胶囊临床研究回顾 有法可依——布地奈德肠溶胶囊已在中国获批,并可申请慈善援助 总结 参考文献 1.Suzuki H, et al. Semin Immunopathol. 2021; 43(5): 669-678. 2.Ohyama Y, et al. J Clin Med. 2021; 10(16): 3467. 3.Shimozato S, et al. Nephrol Dial Transplant. 2008; 23(6): 1931-1939. 4.Kiryluk K, et al. Nat Genet. 2014; 46(11): 1187-1196. 5.Gesualdo L, et al. Semin Immunopathol. 2021; 43(5): 657-668. 6.Kano T, et al. Biomedicines. 2022 ; 10(12): 3027. 7.He JW, et al. Theranostics. 2020; 10(25): 11462-11478. 8.Barratt J, et al. Kidney Int Rep. 2020; 5(10): 1620-1624. 9.TARPEYO. Prescribing Information. Calliditas Therapeutics AB; 2021. 10.Data on file. Calliditas Therapeutics AB. 11.TARPEYO. Prescribing Information. Calliditas Therapeutics AB; 2021. 12.Data on file. Calliditas Therapeutics AB. 13.Brattsand R. Canadian Journal of Gastroenterology. 1990; 4(7): 407–14. 14.Barratt J, et al. Kidney Int. 2023; 103(2): 391-402 . 15.Richard Lafayette, et al. Long-term renal benefit over 2 years with Nefecon verified: The NefIgArd Phase Ⅲ full trial results. Presented at ERA2023. 16.Richard Lafayette, et al.Durable proteinuria reduction over 2 years with Nefecon treatment: A secondary analysis of the full NefIgArd Phase Ⅲ trial results. Presented at ERA2023. 17.Richard Lafayette, et al. 2023 IIgANN. Hematuria reduction in patients with IgAN following Nefecon treatment: A secondary analysis of the full 2-year NeflgArd Phase 3 trial results. 18.2023ASN. Oral presentation. 19.FDA approves first drug to decrease urine protein in IgA nephropathy, a rare kidney disease 20.https://news./calliditas-therapeutics/r/european-commission-approves-kinpeygo--for-adults-with-primary-iga-nephropathy,c3600434 21.https://www.nmpa.gov.cn/zwfw/sdxx/sdxxyp/yppjfb/20231124144653113.html “肾医线”读者专属微信群建好了,快快加入吧。扫描“肾医线”小助手二维码(微信号:nephro-online),回复“肾医线读者”,ta会尽快拉您入群滴! (来源:《肾医线》编辑部) |
|